calico
04-28-2004, 05:59 AM
Whoops! Sorry! Didn't realize Dr. Wise had already posted on this.
Calico
SOUTH SAN FRANCISCO, Calif., April 2 /PRNewswire-FirstCall/ --
Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced positive pre-clinical data on a novel treatment for neuropathic pain. The Company will present its pre-clinical data at the Scientific
Meeting of the American and Canadian Pain Societies on Friday, May 7, 2004 in Vancouver, Canada.
Pain Therapeutics' new data opens up the possibility of using its technology to treat neuropathic pain, a chronic condition that affects 2 to 3 million Americans and a new area of focus for the Company. "We are excited about the possibility of using our novel technology in the area of neuropathic pain," said Remi Barbier, Pain Therapeutics' president and
chief executive officer. "Moderate-to-severe neuropathic pain is typically poorly managed by existing drugs, is often under-diagnosed and affects a large patient population. We believe a novel drug that provides effective pain
relief would bring significant advantages for patients who endure this chronic condition."
Pain Therapeutics (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-27-2004/0002160465&EDATE=)
[This message was edited by calico on 04-28-04 at 12:36 PM.]
Calico
SOUTH SAN FRANCISCO, Calif., April 2 /PRNewswire-FirstCall/ --
Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced positive pre-clinical data on a novel treatment for neuropathic pain. The Company will present its pre-clinical data at the Scientific
Meeting of the American and Canadian Pain Societies on Friday, May 7, 2004 in Vancouver, Canada.
Pain Therapeutics' new data opens up the possibility of using its technology to treat neuropathic pain, a chronic condition that affects 2 to 3 million Americans and a new area of focus for the Company. "We are excited about the possibility of using our novel technology in the area of neuropathic pain," said Remi Barbier, Pain Therapeutics' president and
chief executive officer. "Moderate-to-severe neuropathic pain is typically poorly managed by existing drugs, is often under-diagnosed and affects a large patient population. We believe a novel drug that provides effective pain
relief would bring significant advantages for patients who endure this chronic condition."
Pain Therapeutics (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-27-2004/0002160465&EDATE=)
[This message was edited by calico on 04-28-04 at 12:36 PM.]